Cover Image

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the safety, tolerability, pharmacokinetics (PK), target occ...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andreas Becker (Author), Emily C. Martin (Author), David Y. Mitchell (Author), Roland Grenningloh (Author), Andrew T. Bender (Author), Julien Laurent (Author), Harald Mackenzie (Author), Andreas Johne (Author)
Format:	Book
Published:	Wiley, 2020-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
by: Orestis Papasouliotis, et al.
Published: (2022)

Concentration-QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation
by: Koen Jolling, et al.
Published: (2019)

Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
by: Ying C. Ou, et al.
Published: (2021)

Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers
by: Naoto Noda, et al.
Published: (2021)

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
by: Holger Scheible, et al.
Published: (2021)

A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers
by: Marie‐José Cabanis, et al.
Published: (2024)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers
by: Kun-Yan Li, PhD, et al.
Published: (2014)

Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers
by: Xiaojie Wu, et al.
Published: (2022)

Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers
by: Himanshu Naik, et al.
Published: (2021)

Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study
by: Orestis Papasouliotis, et al.
Published: (2022)

Pharmacokinetics and Tolerability of Single and Multiple Intravenous Doses of Cefotetan Disodium in Healthy Chinese Volunteers
by: Liu J, et al.
Published: (2020)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
by: Mohammad Al‐Mahdi Al‐Karagholi, et al.
Published: (2021)

Single and multiple dose pharmacokinetics and tolerability of HX-1171, a novel antioxidant, in healthy volunteers
by: Kim YH, et al.
Published: (2015)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
by: David Monteith, et al.
Published: (2017)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers
by: Joseph F. Grippo, et al.
Published: (2021)

Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System
by: Yan Ji, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers
by: Islam R. Younis, et al.
Published: (2023)

Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis
by: Timothy J. Turner, et al.
Published: (2024)

Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers
by: Kim H, et al.
Published: (2018)

Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers
by: Rui Zhu, et al.
Published: (2022)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
by: Xiaojiao Li, et al.
Published: (2018)

Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers
by: Chan Zou, et al.
Published: (2019)

Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension
by: Andreas Becker, et al.
Published: (2023)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
by: Cao T, et al.
Published: (2022)

ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
by: Krishnarup Ghoshdastidar, et al.
Published: (2020)

Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers
by: Shin D, et al.
Published: (2019)

Pharmacokinetics, safety and tolerability of L-3-n-butylphthalide tablet after single and multiple oral administrations in healthy Chinese volunteers
by: Meng Wang, et al.
Published: (2015)

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non‐covalent BTK inhibitor, in healthy subjects: First‐in‐human phase I study
by: Kyoko Miyamoto, et al.
Published: (2024)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
by: Jia Liu, et al.
Published: (2022)

Low Concentrations of Oxidized Phospholipids Increase Stress Tolerance of Endothelial Cells
by: Christina Mauerhofer, et al.
Published: (2022)

A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers
by: Tong Lin, et al.
Published: (2021)

First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers
by: Lisa M. Pitchford, et al.
Published: (2019)

A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers
by: Folke Sjöberg, et al.
Published: (2021)

Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers
by: Lulu Chen, et al.
Published: (2018)

Pharmacokinetics of intranasal amiloride in healthy volunteers
by: Venkata K. Yellepeddi, et al.
Published: (2023)

Drug-induced QT interval prolongation in cancer patients
by: Torben K. Becker, et al.
Published: (2011)

Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis
by: Carnero Contentti E, et al.
Published: (2022)

QT PRODACT: In Vivo QT Assay in the Conscious Dog for Assessing the Potential for QT Interval Prolongation by Human Pharmaceuticals
by: Shigeki Toyoshima, et al.
Published: (2005)

QT PRODACT: In Vivo QT Assay in Anesthetized Dog for Detecting the Potential for QT Interval Prolongation by Human Pharmaceuticals
by: Hiroyuki Tashibu, et al.
Published: (2005)

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
by: Golor G, et al.
Published: (2012)